Strategy Asset Managers LLC Buys 62 Shares of Zoetis Inc. (NYSE:ZTS)

Strategy Asset Managers LLC lifted its stake in Zoetis Inc. (NYSE:ZTS) by 3.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,822 shares of the company’s stock after purchasing an additional 62 shares during the quarter. Strategy Asset Managers LLC’s holdings in Zoetis were worth $356,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of ZTS. Cetera Investment Advisers increased its position in Zoetis by 275.2% during the first quarter. Cetera Investment Advisers now owns 96,085 shares of the company’s stock valued at $16,259,000 after acquiring an additional 70,476 shares during the last quarter. Simplify Asset Management Inc. purchased a new stake in Zoetis in the 3rd quarter worth about $11,684,000. Soltis Investment Advisors LLC bought a new stake in Zoetis in the first quarter worth about $688,000. Bank Pictet & Cie Asia Ltd. lifted its stake in Zoetis by 41.0% in the second quarter. Bank Pictet & Cie Asia Ltd. now owns 37,500 shares of the company’s stock worth $6,501,000 after purchasing an additional 10,900 shares during the last quarter. Finally, Swedbank AB boosted its position in shares of Zoetis by 56.2% during the second quarter. Swedbank AB now owns 1,946,277 shares of the company’s stock valued at $337,407,000 after buying an additional 700,398 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $175.67 on Thursday. The firm has a 50 day moving average of $186.18 and a 200 day moving average of $180.47. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $79.26 billion, a price-to-earnings ratio of 33.02, a price-to-earnings-growth ratio of 2.69 and a beta of 0.90. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the company posted $1.36 EPS. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, sell-side analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio is currently 32.52%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ZTS shares. BTIG Research increased their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. JPMorgan Chase & Co. lifted their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus boosted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.